Patrick Michael Dillon, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Associate Professor
Years: 2010-present

None Reported

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models.
Clin Cancer Research
18(19):5290-303
Date: 08 2012
clincancerres.aacrjournals.org/content/18/19/5290.long

A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.
Oncology
83(6):305-20.
Date: 09 2012
content.karger.com/produktedb/produkte.asp?DOI=10.1159/000341394

Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.
Oncologist
17(10):1303-16
Date: 09 2012
theoncologist.alphamedpress.org/content/17/10/1303.long

Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.
Breast Disease
Volume: 35
Date: 08 2015
www.ncbi.nlm.nih.gov/pubmed/25567000

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Immunotherapy
Volume: 8
Date: 05 2016

Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival.
Oncology
Volume: 91
Date: 06 2016

Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
33
Date: 07 2016

Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center.
Breast Journal
Volume: 22
Date: 07 2016

Cancer treatment-related cardiac toxicity: prevention, assessment and management.
Medical Oncology
Volume: 33
Date: 08 2016

Paraneoplastic neurological complications of breast cancer.
Experimental Hematology & Oncology
Volume: 5
Date: 10 2016